BUSINESS

Setback for Ranbaxy in Ireland on Lipitor case

Source:PTI
July 10, 2007 19:52 IST

In its ongoing patent litigation over cholesterol lowering drug atorvastatin (Lipitor) against India's Ranbaxy Laboratories, Pfizer said on Tuesday in a court in Ireland had ruled in its favour.

The world's largest drugmaker said in a statement that the high court in Dublin had ruled that the basic patent covering atorvastatin -- the active ingredient in Lipitor-- would be infringed by Ranbaxy's generic product.

"The decision, which is subject to a possible appeal, prevents Ranbaxy from launching its drug before the basic Lipitor patent expires in November 2011,"

the Pfizer statement said.

"We remain confident of our position and will file a timely appeal," Ranbaxy spokesperson said. Pfizer General Counsel Allen Waxman said: "Today's decision is yet another affirmation of the strength of the intellectual property behind Lipitor."

It is also an important outcome for Pfizer and other medical innovations who invest in high-risk research to develop life saving medicines, and for the patients who benefit from these medicines, he added.

Source: PTI
© Copyright 2025 PTI. All rights reserved. Republication or redistribution of PTI content, including by framing or similar means, is expressly prohibited without the prior written consent.

NEXT ARTICLE

NewsBusinessMoviesSportsCricketGet AheadDiscussionLabsMyPageVideosCompany Email